Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Paolo Ghia MD

Paolo Ghia MD

Clinical Director, Strategic Research Program on CLL, IRCCS Ospedale San Raffaele; Professor of Medical Oncology, Università Vita Salute San Raffaele, Milano, Italy

Paolo Ghia is currently Professor of Medical Oncology at the Università Vita-Salute San Raffaele; head of the research laboratory on B Cell Neoplasia and Clinical Director of the Strategic Research Program on CLL at the affiliated Ospedale San Raffaele with a particular focus on Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-cell Lymphocytosis (MBL) on which he has published over 350 manuscripts

Paolo Ghia received his MD from the University of Torino, Italy, received his PhD working at the Basel Institute for Immunology, Switzerland; he has been a research associate at the Dana-Farber Cancer Institute, Harvard Medical School, Boston where he is now visiting professor of Medicine.

He is President of the European Research Initiative on CLL (ERIC) and a treasurer of the International Workshop on CLL (iwCLL).

Recent Contributions to PracticeUpdate:

  1. Anti-CD19 CAR T-Cell Therapy for Richter Transformation